Ischemic heart disease after renal transplantation

Slides:

Advertisements

Similar presentations

Renal disease and hypertension in non–insulin-dependent diabetes mellitus Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz Kidney International.

Advertisements

Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages

Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy Francesco Paolo Schena Kidney International Volume 57,

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Ischemic heart disease after renal transplantation

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

LDL cholesterol in CKD—to treat or not to treat?

End-stage renal disease in developing countries

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Volume 79, Issue 9, Pages (May 2011)

Volume 83, Issue 3, Pages (March 2013)

Lipopheresis in the nephrotic syndrome

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Membranous nephropathy: When and how to treat

Kidney transplantation in a low-resource setting: Nigeria experience

Volume 80, Issue 10, Pages (November 2011)

Volume 77, Issue 1, Pages 6-8 (January 2010)

Burden of chronic kidney disease: North Africa

Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Fu L. Luan, Diane E. Steffick,

Ian H. de Boer, Rajnish Mehrotra Kidney International

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

LDL cholesterol in CKD—to treat or not to treat?

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Volume 59, Issue 4, Pages (April 2001)

Fructose intake as a risk factor for kidney stone disease

Arterial function after successful renal transplantation

Bone mass evolution after renal transplantation

Volume 87, Issue 1, Pages (January 2015)

Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation? Lionel Rostaing, Nassim Kamar Kidney International

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske

Volume 93, Issue 1, Pages (January 2018)

Volume 87, Issue 1, Pages (January 2015)

Volume 56, Pages S137-S140 (July 1999)

Volume 85, Issue 1, Pages 3-4 (January 2014)

Volume 67, Issue 4, Pages (April 2005)

The global challenge of chronic kidney disease

Nephrology Crossword: Glomerulonephritis

Volume 56, Pages S235-S237 (July 1999)

Unilateral renal cystic disease

A man with a hole in his penis

Volume 73, Issue 9, Pages (May 2008)

Cardiovascular risk assessment in kidney transplantation

Mediterranean diets: are they practical in the Western world?

Atlas of Diseases of the Kidney

Long-term survival in renal transplant recipients with graft function

Organ transplantation goes to the movies

Volume 60, Issue 5, Pages (November 2001)

Does equal care give equal outcomes?

Atherosclerotic nephropathy

Volume 55, Pages S3-S16 (June 1999)

Volume 63, Issue 6, Pages (June 2003)

Volume 56, Pages S28-S30 (July 1999)

American Indian heritage and risk factors for renal injury

Volume 69, Issue 10, Pages (May 2006)

Is complement a target for therapy in renal disease?

Volume 70, Issue 5, Pages (September 2006)

Hisataka Kobayashi, Peter L. Choyke Kidney International

The international realities of live donor kidney transplantation

Volume 70, Issue 10, Pages (November 2006)

Volume 57, Issue 2, Pages (October 2000)

Ronen Levi, Justin Silver Kidney International

Volume 62, Issue 5, Pages (November 2002)

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Ischemic heart disease after renal transplantation Dr. Bertram L. Kasiske Kidney International Volume 61, Issue 1, Pages 356-369 (January 2002) DOI: 10.1046/j.1523-1755.2002.00121.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Treatment of low-density lipoprotein (LDL) cholesterol after renal transplantation. “Low-potency statins” include, for example, fluvastatin and pravastatin, while atorvastatin is an example of a more expensive “high-potency statin.” Changes in immunosuppression might include: (1) switching from cyclosporine A to tacrolimus, (2) discontinuing or substituting rapamycin, or (3) reducing or discontinuing prednisone. Kidney International 2002 61, 356-369DOI: (10.1046/j.1523-1755.2002.00121.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Kidney International 2002 61, 356-369DOI: (10. 1046/j. 1523-1755. 2002 Kidney International 2002 61, 356-369DOI: (10.1046/j.1523-1755.2002.00121.x) Copyright © 2002 International Society of Nephrology Terms and Conditions